SNNA Sienna Biopharmaceuticals Inc.

3
+0.06  (+2%)
Previous Close 2.94
Open 2.94
Price To Book 1.41
Market Cap 63420303
Shares 21,140,101
Volume 44,327
Short Ratio
Av. Daily Volume 360,836

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data met non-inferiority primary endpoint - February 8, 2019. Seeking partner for further advancement.
SNA-001
Reduction of light-pigmented hair
Phase 3 data released July 30, 2018 did not meet primary endpoint.
SNA-001
Acne
Phase 2b trial did not meet primary endpoint. Phase 3 trial to be initiated 2H 2019.
SNA-120
Pruritus associated with psoriasis
Phase 1/2 data released August 27, 2018.
SNA-125
Psoriasis
Phase 2 trial planned.
SNA-125
Atopic dermatitis

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19608448
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19605171
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19595139
  4. 8-K - Current report 19578143
  5. 8-K - Current report 19550149
  6. 8-K - Current report 19501734
  7. 8-K - Current report 181230112
  8. 8-K - Current report 181212773
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 181168426
  10. 8-K - Current report 181168418